UK scientists showcased their latest work to replace, reduce and refine the use of animals in research and testing at an NC3Rs event held in the House of Lords yesterday (Wednesday 25 March)
Held to celebrate the 50th anniversary of the principles of the 3Rs, the event provided an opportunity for MPs to find out more about scientific and technological advances which are improving research in the biosciences and minimising the use of animals. The event featured 43 posters from scientists based at establishments in the UK, from both academia and industry, and was attended by more than 150 guests, including 30 MPs and Peers.
Lord Drayson, Minister of State for Science and Innovation, presented prizes of £3k for the best poster in each 'R', as decided by a prestigious panel. The posters were judged on the quality of the science, the impact on the 3Rs and importantly the ability of the poster presenters to communicate their research to a non-specialist audience. In addition, to the three winning posters, recognition was also given to highly commended posters.
The prizes went to:
A 3D model of breast cancer: towards replacing the need for animal experiments. Deborah Holiday, University of Leeds
Development of a cell-based diabetic wound bioassay. Matthew Peake, University of Cardiff
Caterpillars as a model to replace mammals used to study fungal infections. Joanne Slater, University of Manchester
Reduction in an animal model used in obesity research. Steven Wang, AstraZeneca
Lighting the way to reduced animal use. Siouxsie Wiles, Imperial College London
An improved technique which has reduced the number of dogs used in the discovery of new inhaled medicines. Karen Wright, Pfizer
Opportunities for refinement and reduction using dried blood spots for generation of toxicokinetic data. Cerys Lovatt, GlaxoSmithKline
Refinement of a standard gastrointestinal (charcoal meal) study. Helen Prior, AstraZeneca
Refinement and reduction of animal use for routine pharmacokinetic experiments using surgically modified animals. Ruth Storer, AstraZeneca